Industry must evolve to adopt hybrid model for future growth

To find sustainable growth and profits, traditional ‘pure-play’ generics companies will have to become hybrid entities that span the spectrum from OTC brands to biosimilars,industry veteran Claudio Albrecht told Aidan Fry in an exclusive interview.